Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
EMD Serono
National Cancer Institute (NCI)
OncoSec Medical Incorporated
Ludwig Institute for Cancer Research
Incyte Corporation
Dana-Farber Cancer Institute
Medical University of Graz